Ansun BioPharma attracts $85 mln Series A
San Diego-based Ansun BioPharma, a developer of anti-viral biologic therapeutics to combat severe viral respiratory tract infections, has closed $85 million in Series A financing. Sinopharm Healthcare Fund and Lilly Asia Ventures led the round with participation from other investors that included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures and Joincap Investment.
15 May 2018•1 min read
